The all-in-one platform to find and track your investments
Discover the features
Statistics
Market Cap
130 billion
PE Ratio
14.18 x
Beta (volatility)
0.4
Earnings Per Share
6.7
About
ISIN : FR0000120578
It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Heal
Price
Performance Comparison
| Sanofi SA | |
|---|---|
| 1 year return |
-2 %
|
| 5 years return |
+74 %
|
Valuation (BETA)
For this company, we show you a quick help in graphical form that tells you if the stock looks overvalued, undervalued or fairly priced, and by how much. Stop paying too much for your shares.
Unlock valuation chart for this company
Dividend History
Uninter. Dividend
+ 30 yr.
Frequency
1x / year
Dividends in 2022
May
Dividends in 2021
May
May
Dividends in 2021
May
Forward Annual Amount
€3.56
Ex-dividend
5/30/2023
Number of Outstanding Shares
Financials
Year-over-Year growth
Profitability
Health
Valuation
| Price to Book | Payout ratio | PE Ratio | PEG Ratio |
|---|---|---|---|
| 1.61 | 50 % | 14.18 x | 1.63 |
| Price to Sales | Price / FCF | Enterprise Value Revenue |
|---|---|---|
| 2.87 | 14.3 | 2.90 |
News
Earnings report announcement
4/27/2023
Sanofi (SNY) Gains But Lags Market: What You Should Know
6/2/2023
Gen Z needs brand new skills to climb to the C-Suite: ‘What got me here will not get them there,’ says healthcare CEO
6/2/2023
Pharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies
6/2/2023
The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge
6/1/2023
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
6/1/2023
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
6/1/2023
Top Stock Reports for FEMSA, NextEra Energy & Sanofi
5/31/2023
Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
5/31/2023
Was This $3 Billion Deal a Wise Move for Sanofi?
5/31/2023
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
5/31/2023
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
5/31/2023
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
5/26/2023
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2023 Epsylia OÜ - All rights reserved